PMID: 7539852Jul 1, 1995Paper

Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia

The Journal of Urology
L M EriA G Bechensteen

Abstract

The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia. In the 26 patients receiving leuprolide the mean total cholesterol level increased by 10.6%, high density lipoprotein cholesterol by 8.2% and triglycerides by 26.9% (p = 0.003, 0.052 and 0.050, respectively). Low density lipoprotein cholesterol levels were unchanged. Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged. Hemoglobin decreased by 1.2 gm./100 ml. without a concomitant decrease in serum erythropoietin concentration. These changes act in different directions with regard to cardiovascular risk and the overall effect is difficult to assess.

References

Jan 1, 1992·Seminars in Thrombosis and Hemostasis·C Krishnamurti, B M Alving
Jun 15, 1992·Annals of Internal Medicine·C J BagatellW J Bremner
Sep 1, 1991·Atherosclerosis·M Seed
Aug 8, 1991·The New England Journal of Medicine·M J StampferC H Hennekens
Oct 1, 1985·Steroids·W Fried, C Morley
May 1, 1981·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·L Wallentin, E Varenhorst
Jun 1, 1993·British Journal of Urology·D A GillattJ C Gingell

❮ Previous
Next ❯

Citations

Nov 5, 2009·Journal of General Internal Medicine·Philip J SaylorMatthew R Smith
Aug 14, 2003·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Arnold von Eckardstein, Fredrick C W Wu
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity·Matthew R Smith
May 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip J SaylorMatthew R Smith
Feb 4, 2010·Circulation·Glenn N LevineUNKNOWN American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer So
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason A EfstathiouMatthew R Smith
Apr 8, 2011·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Hassanabbas Z MohamedaliShabbir M H Alibhai
Jan 1, 1996·Urology·G J Kolvenbag, G R Blackledge
Oct 28, 2015·Prostate Cancer and Prostatic Diseases·K MitsuzukaUNKNOWN Michinoku Urological Cancer Study Group
Feb 25, 2015·Nature Reviews. Urology·Jahan J MohiuddinRonald C Chen
Apr 27, 2016·Nature Reviews. Urology·Peter Busch ØstergrenMikkel Fode
Jun 29, 2016·Prostate Cancer and Prostatic Diseases·J L KiwataC M Dieli-Conwright
Apr 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R SmithMitchell S Steiner
Dec 30, 2014·The Journal of Urology·Juan MoroteUNKNOWN ANAMET Investigators Group
Jul 21, 2017·American Journal of Men's Health·Edyta Idalia Wolny-RokickaAgnieszka Zembroń-Łacny
Apr 22, 2015·Journal of the American Heart Association·Paul L NguyenJoshua A Beckman
Jan 20, 2015·Korean journal of urology·See Min Choi, Sung Chul Kam
Dec 19, 2012·The Journal of Urology·Philip J Saylor, Matthew R Smith
Mar 17, 2009·The Journal of Urology·Philip J Saylor, Matthew R Smith
Apr 18, 2003·Endocrine Reviews·Fredrick C W Wu, Arnold von Eckardstein
Apr 17, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Donovan A McGrowderTazhmoye V Crawford

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.